mismatch repair deficiency
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy in Certain Colorectal Cancers
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
Tizona Therapeutics Expands Phase Ib Trial to Include Biomarker-Selected Colorectal Cancer Cohorts
In the new arms, patients with certain biomarker-defined tumors will receive either an HLA-G targeted antibody, chemo, and Erbitux, or just chemo and Erbitux.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined subset relative to all-comers.
ROME Trial Shows Benefit of Tumor-Agnostic Targeted Therapy Guided by a Molecular Tumor Board
Premium
Patients on therapies recommended by an MTB had better progression-free survival and overall response rates than those on standard-of-care therapy.
Merck's Keytruda Added to Adjuvant Chemo Benefits Newly Diagnosed Endometrial Cancer Subpopulation
Premium
The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.